{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:44:58Z","timestamp":1791053098082,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The application of evidence-based medicine to the management of adults with sickle cell disease (SCD) is currently primarily driven by clinical expertise and patient preference, as there is a paucity of randomized controlled trial (RCT) data to guide decision-making. A summary of SCD management principles in the areas of health care maintenance, transfusion therapy, treatment and prevention of painful episodes, acute chest syndrome, stroke, renal disease, contraception and pregnancy, and priapism is predominantly based on the authors\u2019 interpretation of available observational studies as well as the opinions of experts in SCD. RCTs impacting current practices address use of hydroxyurea to prevent painful episodes and acute chest syndrome, intensity of pre-operative transfusion, transfusion during pregnancy, and angiotensin-converting enzyme inhibitor therapy for proteinuria, but most issues in adult SCD care have not been rigorously studied and management may not be appropriately extrapolated from pediatric data. While challenging clinical problems need to be addressed by RCTs, there is also the need for development of practice guidelines using formal methodological strategies. This brief review is not a substitute for the process but provides a literature-based approach to making treatment decisions when caring for adults with SCD.<\/jats:p>","DOI":"10.1182\/asheducation-2005.1.58","type":"journal-article","created":{"date-parts":[[2005,11,22]],"date-time":"2005-11-22T20:29:34Z","timestamp":1132691374000},"page":"58-65","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":62,"title":["An Evidence-Based Approach to the Treatment of Adults with Sickle Cell Disease"],"prefix":"10.1182","volume":"2005","author":[{"given":"Richard","family":"Lottenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn L.","family":"Hassell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111702154962800_R1","doi-asserted-by":"crossref","unstructured":"Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn\u2019t. Br Med J. 1996;312:71\u201372.","DOI":"10.1136\/bmj.312.7023.71"},{"key":"2019111702154962800_R2","unstructured":"The Management of Sickle Cell Disease. 4th ed. Bethesda, MD: National Institutes of Health. National Heart, Lung, and Blood Institute; 2002."},{"key":"2019111702154962800_R3","unstructured":"U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Alexander, VA: International Medical Publishing; 1996."},{"key":"2019111702154962800_R4","doi-asserted-by":"crossref","unstructured":"Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med. 1997;102:171\u2013177.","DOI":"10.1016\/S0002-9343(96)00407-X"},{"key":"2019111702154962800_R5","unstructured":"Rosse WF, Telen M, Ware R. Transfusion Support for Patients with Sickle Cell Disease. Bethesda, MD: American Association of Blood Banks; 1998."},{"key":"2019111702154962800_R6","doi-asserted-by":"crossref","unstructured":"Vichinsky, E. Consensus document for transfusion-related iron overload. Semin Hematol. 2001;38 Suppl 1:2\u20134.","DOI":"10.1016\/S0037-1963(01)90054-X"},{"key":"2019111702154962800_R7","doi-asserted-by":"crossref","unstructured":"Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion. 2001;41:1086\u20131092.","DOI":"10.1046\/j.1537-2995.2001.41091086.x"},{"key":"2019111702154962800_R8","doi-asserted-by":"crossref","unstructured":"Kwiatkowski JL, Cohen AR. Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias. Hematol Oncol Clin North Am. 2004;18:1355\u20131377.","DOI":"10.1016\/j.hoc.2004.06.019"},{"key":"2019111702154962800_R9","doi-asserted-by":"crossref","unstructured":"Bellet PS, Kalinyak KA, Shukla R, Gelfand MJ, Rucknagel DL. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med. 1995;333:699\u2013703.","DOI":"10.1056\/NEJM199509143331104"},{"key":"2019111702154962800_R10","doi-asserted-by":"crossref","unstructured":"Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med. 1994;330:733\u2013737.","DOI":"10.1056\/NEJM199403173301101"},{"key":"2019111702154962800_R11","doi-asserted-by":"crossref","unstructured":"Weiner DL, Hibberd PL, Betit P, Cooper AB, Botelho CA, Brugnara C. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA. 2003;289:1136\u20131142.","DOI":"10.1001\/jama.289.9.1136"},{"key":"2019111702154962800_R12","doi-asserted-by":"crossref","unstructured":"Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA. 2001;286:2099\u20132106.","DOI":"10.1001\/jama.286.17.2099"},{"key":"2019111702154962800_R13","doi-asserted-by":"crossref","unstructured":"Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood. 2000;95:1130\u20131136.","DOI":"10.1182\/blood.V95.4.1130.003k03a_1130_1136"},{"key":"2019111702154962800_R14","doi-asserted-by":"crossref","unstructured":"Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342:1855\u20131865.","DOI":"10.1056\/NEJM200006223422502"},{"key":"2019111702154962800_R15","doi-asserted-by":"crossref","unstructured":"Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317\u20131322.","DOI":"10.1056\/NEJM199505183322001"},{"key":"2019111702154962800_R16","doi-asserted-by":"crossref","unstructured":"Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. N Engl J Med. 1988;319:1447\u20131452.","DOI":"10.1056\/NEJM198812013192204"},{"key":"2019111702154962800_R17","doi-asserted-by":"crossref","unstructured":"Boyd JH, Moinuddin A, Strunk RC, Debaun MR. Asthma and acute chest in sickle-cell disease. Pediatr Pulmonol. 2004;38:229\u2013232.","DOI":"10.1002\/ppul.20066"},{"key":"2019111702154962800_R18","doi-asserted-by":"crossref","unstructured":"Bernini JC, Rogers ZR, Sandler ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood. 1998;92:3082\u20133089.","DOI":"10.1182\/blood.V92.9.3082"},{"key":"2019111702154962800_R19","doi-asserted-by":"crossref","unstructured":"Hankins J, Jeng M, Harris S, et al. Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome. J Pediatr Hematol Oncol. 2005;27:158\u2013161.","DOI":"10.1097\/01.mph.0000157789.73706.53"},{"key":"2019111702154962800_R20","doi-asserted-by":"crossref","unstructured":"Miller ST, Wright E, Abboud M, et al; STOP Investigators. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2002;141:742\u2013743.","DOI":"10.1067\/mpd.2002.128754"},{"key":"2019111702154962800_R21","doi-asserted-by":"crossref","unstructured":"Wang WC, Kovnar EH; Tonkin IL, et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr. 1991;118:377\u2013382.","DOI":"10.1016\/S0022-3476(05)82150-X"},{"key":"2019111702154962800_R22","doi-asserted-by":"crossref","unstructured":"Cohen AR, Martin MB, Silber JH, et al. A modified transfusion program for prevention of stroke in sickle cell disease. Blood. 1992;79:1657\u20131661.","DOI":"10.1182\/blood.V79.7.1657.1657"},{"key":"2019111702154962800_R23","doi-asserted-by":"crossref","unstructured":"Scothorn DJ, Price C, Schwartz D, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr. 2002;140:348\u2013354.","DOI":"10.1067\/mpd.2002.122498"},{"key":"2019111702154962800_R24","doi-asserted-by":"crossref","unstructured":"Ware RE, Zummerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145:346\u2013352.","DOI":"10.1016\/j.jpeds.2004.04.058"},{"key":"2019111702154962800_R25","doi-asserted-by":"crossref","unstructured":"Dobson SR, Holden KR, Nietert PJ, et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood. 2002;99:3144\u20133150.","DOI":"10.1182\/blood.V99.9.3144"},{"key":"2019111702154962800_R26","doi-asserted-by":"crossref","unstructured":"Fryer RH, Anderson, RC, Chiriboga, CA, et al. Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure. Pediatr Neurol. 2003;29:124\u201330.","DOI":"10.1016\/S0887-8994(03)00047-X"},{"key":"2019111702154962800_R27","doi-asserted-by":"crossref","unstructured":"Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5\u201311.","DOI":"10.1056\/NEJM199807023390102"},{"key":"2019111702154962800_R28","doi-asserted-by":"crossref","unstructured":"Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med. 1995;333:206\u2013213.","DOI":"10.1056\/NEJM199507273330402"},{"key":"2019111702154962800_R29","unstructured":"Haberkern CM, Neumayr LD, Orringer EP, et al. Cholecystectomy in sickle cell anemia patients: perioperative outcome of 364 cases from the National Preoperative Transfusion Study. Preoperative Transfusion in Sickle Cell Disease Study Group. Blood. 1997;89:1533\u20131542."},{"key":"2019111702154962800_R30","doi-asserted-by":"crossref","unstructured":"Neumayr L, Koshy M, Haberkern C, et al. Surgery in patients with hemoglobin SC disease. Preoperative Transfusion in Sickle Cell Disease Study Group. Am J Hematol. 1998;57:101\u2013108.","DOI":"10.1002\/(SICI)1096-8652(199802)57:2<101::AID-AJH2>3.0.CO;2-#"},{"key":"2019111702154962800_R31","unstructured":"Aoki RY, Saad ST. Microalbuminuria in sickle cell disease. Braz J Med Biol Res. 1990;23:1103\u20131106."},{"key":"2019111702154962800_R32","doi-asserted-by":"crossref","unstructured":"Falk RJ, Scheinman J, Phillips G, Orringer E, Johnson A, Jennette JC. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N Engl J Med. 1992;326:910\u2013915.","DOI":"10.1056\/NEJM199204023261402"},{"key":"2019111702154962800_R33","doi-asserted-by":"crossref","unstructured":"Foucan L, Bourhis V, Bangou J, et al. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. Am J Med. 1998;104:339\u2013342.","DOI":"10.1016\/S0002-9343(98)00056-4"},{"key":"2019111702154962800_R34","doi-asserted-by":"crossref","unstructured":"Ojo AO, Govaerts TC, Schmouder RL, et al. Renal transplantation in end-stage sickle cell nephropathy. Transplantation. 1999;67:291\u2013295.","DOI":"10.1097\/00007890-199901270-00018"},{"key":"2019111702154962800_R35","doi-asserted-by":"crossref","unstructured":"Smith JA, Espeland M, Bellevue R, et al. Pregnancy in sickle cell disease: experience of the Cooperative Study of Sickle Cell Disease. Obstet Gynecol. 1996;87:199\u2013204.","DOI":"10.1016\/0029-7844(95)00367-3"},{"key":"2019111702154962800_R36","doi-asserted-by":"crossref","unstructured":"Sun PM, Wilburn W, Raynor BD, Jamieson D. Sickle cell disease in pregnancy: twenty years of experience at Grady Memorial Hospital, Atlanta, Georgia. Am J Obstet Gynecol. 2001;184:1127\u20131130.","DOI":"10.1067\/mob.2001.115477"},{"key":"2019111702154962800_R37","doi-asserted-by":"crossref","unstructured":"Serjeant GR, Loy LL, Crowther M, Hambleton IR, Thame M. Outcome of pregnancy in homozygous sickle cell disease. Obstet Gynecol. 2004;103:1278\u20131285.","DOI":"10.1097\/01.AOG.0000127433.23611.54"},{"key":"2019111702154962800_R38","doi-asserted-by":"crossref","unstructured":"Morrison JC, Morrison FS, Floyd RC, et al. Use of continuous flow erythrocytapheresis in pregnant patients with sickle cell disease. J Clin Apheresis. 1991;6:224\u2013229.","DOI":"10.1002\/jca.2920060411"},{"key":"2019111702154962800_R39","doi-asserted-by":"crossref","unstructured":"Mantadakis E, Ewalt DH, Cavender JD, et al. Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism. Blood. 2000;95:78\u201382.","DOI":"10.1182\/blood.V95.1.78"},{"key":"2019111702154962800_R40","doi-asserted-by":"crossref","unstructured":"Saad ST, Lajolo C, Gilli S, et al. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. Am J Hematol. 2004;77:45\u201349.","DOI":"10.1002\/ajh.20142"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/58\/644959\/058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/58\/644959\/058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T02:16:07Z","timestamp":1573956967000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2005\/1\/58\/19252\/An-EvidenceBased-Approach-to-the-Treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2005.1.58","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}